Abstract
Anxiety, and the depressive disorders with which anxiety is frequently comorbid, constitute an enormous illness burden in the US and elsewhere. Approvals of new drug treatments for these disorders have slowed in recent years, largely because preclinical studies have not predicted efficacy well in clinical trials. Detailed analyses of response to threat in laboratory rodents suggest a part…